ISSN: 2476-2024

Diagnostic Pathology: Open Access
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
  • Research Article   
  • Diagnos Pathol Open
  • DOI: 010.4172/2476-2024.7.S11.1000004

Antiphospholipid Antibodies in Patients with COVID-19: Trend over Time

Silvia Mancuso1, Simona Truglia1*, Valeria Riccieri1, Cristiano Alessandri1, Flavia Pasquali1, Fabrizio Conti1, Antonella Capozzi2, Maurizio Sorice2, Gloria Riitano2, Roberta Misasi2 and Claudio Maria Mastroianni3
1Department of Clinical Internal, Anesthetic and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy
2Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy
3Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy
*Corresponding Author: Dr. Simona Truglia, Department of Clinical Internal, Anesthetic and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy, Email: simona.truglia@uniroma1.it

Received: 18-May-2022 / Manuscript No. DPO-22-64098 / Editor assigned: 23-May-2022 / PreQC No. DPO-22-64098(PQ) / Reviewed: 06-Jun-2022 / QC No. DPO-22-64098 / Revised: 13-Jun-2022 / Manuscript No. DPO-22-64098(R) / Published Date: 20-Jun-2022 DOI: 010.4172/2476-2024.7.S11.1000004

Abstract

Objective: Aim of the study was to investigate whether aPL positivity correlated with thrombosis in COVID-19 patients and whether it was transient or persistent.

Methods: We enrolled COVID-19 patients who underwent aPL tests: Lupus Anticoagulant (LA); IgM, IgG, IgA anticardiolipin antibodies (aCL); and IgM, IgG anti-β2-Glycoprotein-I antibodies (aβ2GPI).

Results: Twenty-eight out of 73 (38.4%) patients resulted positive for at least one aPL assay: 32.8% for IgA aCL, 6.8% for IgM aCL and 4.1% for IgM aβ2GPI. No patients tested positive for IgG aPL or LA at the first determination. Seven (9.6%) patients developed thrombotic events during hospitalization, with 4 of them resulting positive for aPL.

In patients with thrombotic events during hospitalization the risk of death was increased 9-fold (LR+8.9, p=0.003). Patients with double positivity for aCL and aβ2GPI IgM had a LR+ of 6.3 to have thrombotic events (p=0.012) and a LR+ of 4.9 to have elevated D-dimer levels (p=0.027). In 10 out of 28 positive patients, aPL was detected in a second occasion at least 12-weeks apart and two patients confirmed the positivity.

Conclusions: Results suggest that double positivity for aCL and aβ2GPI IgM increases the risk of thrombosis in COVID-19, unlike IgA aCL positivity. APL positivity may be persistent, and it is advisable to monitor it over time.

Keywords: Antiphospholipid antibodies; COVID-19; Thrombosis; Persistent positivity

Introduction

Since the beginning of the SARS-CoV-2 outbreak, antiphospholipid antibodies (aPL), a known thrombotic risk factor, have been studied in COVID-19 patients, in whom thromboembolic events have been associated with poor prognosis [1]. The association between infections and aPL is historically known, causing transient positivity for aPL or representing the so-called “second hit” in causing thrombosis in APS patients [2]. The prevalence of aPL in COVID-19 patients is variable, ranging from 8.3% to 74% [3-6]. Furthermore, these studies are heterogeneous and difficult to compare: in some studies, aPL has been searched in critical COVID-19 patients, a condition associated with a greater thrombotic risk [5], in others aPL has been tested in patients with varying degrees of COVID-19 severity [7]. In addition, aPL levels are not reported in all studies and LA was sometimes performed in patients on anticoagulant therapy, with the risk of false positivity [8,9]. To date, the pathogenetic role of aPL and the antibodies trend over time are still unknown. Aim of the present study was to investigate whether aPL positivity correlated with thrombosis in COVID-19 patients and whether it was transient or persistent.

Materials and Methods

Patients

We included all consecutive COVID-19 patients hospitalized in one of the COVID-19 Units of the Policlinico Umberto I, Sapienza University of Rome from April 1, 2020 to June 7, 2020 in this prospective study. The diagnosis of SARS-CoV-2 infection was confirmed in all the patients by nasopharyngeal swab for SARS-CoV-2 on real- time Reverse-Transcriptase–Polymerase-Chain-Reaction (RT-PCR). Patients ‘exclusion criteria were: Non-COVID-19 patients and patients affected by Autoimmune Inflammatory Rheumatic Diseases (AIIRD). This study was approved by the local ethic committees and participants gave written informed consent.

Methods

IgG and IgM aCL and aβ2-GPI were detected by chemiluminescence assay using Zenit RA Immunoanalyzer (A. Menarini Diagnostics, Florence, Italy), IgA aCL by EliA detection kit by ThermoFisher Scientific (Waltham, USA). LA was analyzed using two coagulation systems, a dilute sensitized activated partial thromboplastin time (aPTT) and a Dilute Russell’s Viper Venom Time (dRVVT), and then performing a confirmatory test with reagents and instrumentation by Hemoliance Instrumentation Laboratory, Lexington, MA, USA.

Statistical analysis

Data are expressed as mean ± Standard Deviation (S.D.) or median (interquartile range) according to the distribution of the variables. χ2-test or Fisher exact test was used for comparison of categorical variables. P values<0.05 were considered statistically significant. SPSS 20.0 statistical software package (SPSS Inc., Chicago, IL, USA) was utilized for all statistical tests.

Results

We enrolled 73 hospitalized patients affected by COVID-19 (40 females and 33 males, all Caucasian) with a mean age of 65 years (SD. 17.6). Clinical and demographic characteristics of COVID-19 are reported in (Table 1). The most common symptoms at disease onset were fever (82%), dyspnea (60%) and cough (31.5%); the median time from appearance of the first symptoms to hospital admission and positive nasopharyngeal swab for SARS-CoV-2 on RT-PCR assay was 5 days (IQR 9.25). In 64 out of 73 patients (87.7%) bilateral distribution of patchy shadows or ground-glass opacity were found in High Resolution Computed Tomography (HRCT) of the chest, the remaining patients did not show any sign of pneumonia. Almost all patients (75%) reported at least one comorbidity; in addition, 8 (10.9%) patients presented a medical history of arterial thrombosis and one (1.4%) patient reported a history of venous thrombosis.

Features 73 Covid-19 patients
Age-year mean (S.D.) 65 (17.6)
Female 40
Comorbidities 55
Hypertension 24
Diabetes 15
Cardiovascular disease 9
Chronic obstructive pulmonary disease or asthma 6
Malignancy 6
History of arterial thrombosis 8
History of venous thrombosis 1
Signs and symptoms, median (IQR)
Fever 60
Dyspnea 44
Cough 23
Diarrhea 4
Chest pain 1
Ageusia/Anosmia 4
HRCT chest: Bilateral ground glass opacity 64
Baseline laboratory values, median (IQR)
Lymphocyte count, cells/L 1350 (1010)
Lactate dehydrogenase, U/L 226 (98.5)
Ferritin ug/L 332.5 (445.5)
D-dimer mcg/L 734 (846)
PaO2:FIO2, mmHg 376 (132)

Table 1: Clinical and demographic features of the 73 Covid-19 patients.

Twenty eight out of 73 (38.4%) patients were found positive for at least one aPL assay at low-medium titer. Twenty-four out of 73 (32.8%) patients showed positivity for IgA aCL, 5/73 (6.8%) for IgM aCL and 3/73 (4.1%) for IgM aβ2GPI. Among the positive patients 24 out 28 (85.7%) patients showed positivity for IgA aCL, 5/28 (17.8%) were found positive for IgM aCL and 3/28 (10.7%) for IgM aβ2GPI. IgG aCl and IgG aβ2GPI were negative in all patients. At the time of hospitalization, LA test was performed only in 12 patients who were not on anticoagulant therapy, no patients tested positive.

Seven out 73 (9.6%) patients developed thrombotic events during hospitalization, among them 4 (57%) tested positive for aPL (Table 2).

Features Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Patient 7
Age-year 67 78 83 43 70 74 95
Sex Female Female Female Male Male Female Male
Medical History Malignancy, Hypertension Stroke Chronic obstructive pulmonary disease No medical history Chronic obstructive pulmonary disease, Hypertension Malignancy Hypertension
Initial findings
Signs and symptoms Dyspnea Dyspnea Dyspnea Fever, ageusia/anosmia, chest pain Fever, cough Dyspnea Dyspnea
HRCT chest: Bilateral ground glass opacity yes yes yes yes yes yes yes
Baseline laboratory values
Lymphocyte count, cells x 106/L 220 210 2330 1580 1680 600 1390
Lactate dehydrogenase, U/L 223 321 199 227 226 349 199
Ferritin mcg/L 614 317 213 387 462 2455 197
D-dimer mcg/L 730 1213 2912 282 688 1298 1097
PaO2:FIO2, mm Hg 132 120 442 534 348 493 314
Anticoagulant therapy at the time of the thrombotic event Therapeutic dosage Prophylactic dosage Prophylactic dosage Not administered Therapeutic dosage Therapeutic dosage Therapeutic dosage
Thrombotic events Stroke Pulmonary embolism Peripheral venous thrombosis Myocardial infarction Pulmonary embolism Myocardial infarction, peripheral arterial thrombosis, peripheral venous thrombosis Peripheral venous thrombosis
Antiphospholipid antibodies IgA aCL IgM aCl 24 MPL, anti-IgM β2glicoprotein I 25 U/mL Negative Negative Negative IgM aCl (23 MPL), anti-IgM β2glicoprotein I 22 U/mL IgA aCL
Outcome Exitus Exitus Suicide Discharged Discharged Discharged Exitus
Antiphospholipid antibodies tested after at least 12 weeks NP NP NP NP NP Negative NP

Table 2: Clinical and demographic features of the 7 Covid-19 patients that developed thrombotic events.

We observed that the risk of death was 9-fold higher in patients with thrombotic events during hospitalization (likelihood positive ratio (LR+) 8.9, p=0.003) and that patients with double positivity for IgM aCL and IgM aβ2GPI had a LR+ of 6.3 to have thrombotic events (p=0.012) and a LR+ of 4.9 to have an increase in D-dimer levels (p=0.027). IgA aCL, the most prevalent aPL, did not result associated with thrombosis.

At follow-up, 10 out of the 28 aPL positive patients died, 8/28 were lost to follow-up. Ten aPL positive patients, 3 men and 7 women (mean age of 55.9 years (S.D. 20.8)), were tested for aPL on a second occasion at least 12 weeks apart from the first determination. None of them had a previous medical history of thrombosis, one patient reported an obstetrical history of 2 fetal deaths.

Overall, only 2/10 (20%) patients confirmed the positivity for at least one aPL assay. These patients tested positive for LA while at the first determination were positive for IgA aCL; at baseline LA test was not performed as they were on anticoagulant therapy. Both 2 patients had no previous or recent history of arterial and/or venous thrombosis, pregnancy morbidities or extra-criteria manifestations suggestive of APS.

Among the 4 patients who developed at least one thromboembolic event during hospitalization and who tested positive for aPL at the first determination, it was possible to repeat the aPL tests after 12 weeks only in one patient (a 74 years-old female) who had experienced three thrombotic events (myocardial infarction, peripheral arterial thrombosis, peripheral venous thrombosis) and she was found negative. The other 3 patients died during hospitalization due to complications of SARS-CoV-2 infection.

Discussion

The results of the present study confirm that thrombotic events increase the risk of death in COVID-19 patients. In addition, we showed that, in COVID-19 patients, double positivity for IgM aCL and IgM aβ2GPI could increase the risk of thrombotic events. For the first time, in this study, we evaluated the persistence of aPL after 12 weeks since the first determination.

It’s well known that infections may lead to transient aPL positivity without clinical manifestations or trigger aPL-related features. To explain such phenomena various possible mechanisms have been proposed, such as molecular mimicry, post-translational modifications, exposition of self-antigens on the cell surface [10]. A wide variety of infectious agents have been linked to aPL positivity, such as CMV, EBV, HIV, HBV, HCV and parvovirus B19 [11,12]. In a systematic review, aPL have been detected in 293 patients during 50 different infections.

Among these patients, 72 patients fulfilled APS criteria, 128 patients reported a thrombotic event in association with a transient aPL positivity and 93 patients did not show any association between aPL and APS-related features [13].

In patients with SARS-CoV-2 infection, aPL has been detected in a variable range of subjects (8.3%-74%) [3-6]. In our study, 38.4% of COVID-19 patients showed positivity for at least one aPL assay at low-medium titer. In agreement with a previous Chinese study, the IgA isotype was found to be the most prevalent aPL in our cohort; those authors suggested that SARS-CoV-2 may preferentially induce the IgA isotype of aPL due to SARS-CoV-2 mucosal tropism. [4]. In our study IgA aCL wasn’t associated with thrombotic events, therefore IgA aCL could be an epiphenomenon.

The possible pathogenetic role of aPL in COVID-19 is still far from being clear; we observed that COVID-19 patients with double positivity for IgM aCL and IgM aβ2GPI have a 6-fold increased risk of thrombotic events and a 5-fold increased risk of higher D-dimer plasma levels. Besides, thrombotic events appeared to increase the risk of death (LR ± 8.9, p=0.003).

Xiao and colleagues evaluated the dynamic changes in aPL levels in 6 COVID-19 patients over a period of 60 to 77 days from disease onset; the results obtained suggest that aPL levels are fluctuating and they encouraged further studies with a long-term follow-up on COVID-19 patients positive for aPL [4]. Indeed, to date, only 2 case reports have tested aPL on a second occasion after at least three months in aPL positive COVID-19 patients [14,15].

At the best of our knowledge, this is the first study in which aPL- positive COVID-19 patients were re-tested after at least 12 weeks apart. The results of our study suggest that the 20% of COVID-19 patients may show persistent positivity for aPL. Given that aPL is a thrombotic risk factor, it may be appropriate to monitor antibodies trend over time and minimize other thrombotic risk factors in patients with SARS- CoV-2 infection.

The main limitations of our study are represented by the small sample size and the one-center design. Our results should be validated in larger and multicenter studies.

Conclusion

In conclusion, the results of our study confirm that thrombotic events increase the risk of death in COVID-19 patients and suggest that double positivity for aCL and aβ2GPI IgM could increase the risk of thrombosis in patients, unlike positivity for IgA aCL.

Antiphospholipid antibodies positivity resulted to be persistent in a small percentage of COVID-19 patients, given that aPL is a thrombotic risk factor, it may be appropriate to monitor antibodies trend over time and minimize other thrombotic risk factors in patients with SARS- CoV-2 infection.

Funding

No specific funding was received from any bodies in the public, commercial or not-for-profit sectors to carry out the work described in this article.

Conflicts of Interest

None declared.

References

Citation: Mancuso S, Truglia S, Riccieri V, Alessandri C, Pasquali F, et al. (2022) Antiphospholipid Antibodies in Patients with COVID-19: Trend over Time. Diagnos Pathol Open 7: 004. DOI: 010.4172/2476-2024.7.S11.1000004

Copyright: © 2022 Mancuso S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Top